Getting you a comprehensive analysis of the product
Reading every ingredient in the formula…
Getting you a comprehensive analysis of the product
Reading every ingredient in the formula…
Join The Clean Sheet™ community
Science-backed beauty tips, ingredient alerts, and early access. Straight to your WhatsApp.
Join for free →Pirfesca Scar Gel stands out with robust clinical backing for its scar-reducing claims, making it a credible option, though consumers need to navigate varied pricing and fragmented ingredient information online.
₹629 • Analysed 22 October 2026
Pirfesca Scar Gel, with its 8% Pirfenidone and silicone base, is positioned as a clinically-backed solution for scar management in the Indian market. The pricing, while premium, sees frequent discounts across e-pharmacies, making it accessible. Its claims of reducing hypertrophic scars are well-supported by clinical studies, which is crucial for Indian consumers prone to post-inflammatory hyperpigmentation and keloid scarring. The 'dermatologically tested' and 'suitable for all skin types' claims are also substantiated by safety studies, addressing common consumer concerns in a tropical climate.
Independent and free. The Clean Sheet takes no money from brands to analyse, rank, or approve a product. This is a web evidence analysis, not a Clean Sheet certification. We checked the ingredient list, publicly available test reports, marketing claims, and formula logic using only public information available at the time of analysis.
Pirfenidone, the key active, has demonstrated anti-fibrotic properties in clinical studies, reducing collagen buildup and supporting skin healing. A controlled clinical trial on 8% pirfenidone gel showed statistically significant scar regression in pediatric burn patients, suggesting a preventative effect on scar progression.
A controlled clinical trial on 8% pirfenidone gel showed continuous monthly statistically significant scar regression over 6 months, with 27% of patients showing >55% decrease in Vancouver Scar Scale scores. The study concluded it was more effective than pressure therapy in treating hypertrophic scars.
The clinical trial using 8% pirfenidone gel showed improvement in all scar features, which includes softening and flattening, as measured by the Vancouver Scar Scale. Pirfenidone works by inhibiting excessive collagen production.
While the clinical study on pirfenidone gel showed overall scar regression and improvement in scar features, specific quantification of 'lightening' was not detailed in the summaries. However, improved texture and reduced redness (inflammation management) can contribute to a lighter appearance.
The clinical trial demonstrated significant scar regression and improvement in overall scar features, which directly relates to improved skin texture. Reduced redness and inflammation also contribute to a more even skin tone.
A safety evaluation study for Pirfesca (PIRFENIDONE GEL 8% w/w) assessed comedogenicity, skin irritability, allergenicity, and photoirritation, concluding it is non-irritant, hypoallergenic, non-comedogenic, and non-photoirritant.
The gel format and presence of silicones (Polydimethylsiloxane, Cyclopentasiloxane, Phenyl Trimethicone, Dimethicone) support claims of non-greasy and fast-absorbing texture. This is a common characteristic of silicone-based gels.
The safety evaluation study confirmed the product is non-irritant, hypoallergenic, non-comedogenic, and non-photoirritant, supporting its suitability for various skin types.
What we could confirm from public sources and the verified ingredient list.
Ingredient Safety & Toxicity
Full ingredient list retrieved and verified against the label.
Screened against the ingredient database (4 of 9 ingredients matched); no cosmetics-prohibited ingredient found.
Cyclopentasiloxane: D5 bioaccumulates in aquatic environment Methylparaben: Weak estrogenic activity
No IARC-classified or formaldehyde-releasing ingredient found in the database screen.
No commonly-comedogenic ingredient found - a reasonable fit for acne-prone skin.
Irritation & Allergen Risk
No EU-declarable or database-flagged allergen found in the list.
No high-sensitisation preservative (MI/MCI/formaldehyde-releaser) from our screen was found.
Brand claims dermatologist testing (claim stated; underlying report not seen).
Ingredient Transparency
The full INCI list is publicly available, not just hero ingredients.
Active percentages are disclosed for the hero ingredient(s).
Ingredients are listed in the descending order required by India Cosmetics Rules 2020.
Standards & Compliance
Usage warnings and directions are clear on the label.
No retinoid or other pregnancy-cautioned active found in the screen.
Screened against a curated reference set that we are continuing to verify and expand, so “clear” means no flag from that set, not a guarantee. Not a substitute for a full toxicological or clinical assessment.
| Ingredient |
|---|
Purified Water |
Diethylene Glycol Monoethyl Ether |
Pirfenidone |
Polydimethylsiloxane |
Cyclopentasiloxane |
Phenyl Trimethicone |
Dimethicone |
Polyacrylate Crosspolymer-6 |
Methylparaben |
INCI order as declared on packaging. Position reflects approximate concentration (high to low).
No prohibited or restricted ingredients identified
No prohibited or restricted ingredients identified
No prohibited or restricted ingredients identified
No prohibited or restricted ingredients identified
No prohibited or restricted ingredients identified
No prohibited or restricted ingredients identified
No prohibited or restricted ingredients identified
No prohibited or restricted ingredients identified
No prohibited or restricted ingredients identified
No prohibited or restricted ingredients identified
Flags are based on publicly available INCI only. Not a substitute for full regulatory compliance assessment.
Pirfenidone, the key active, has demonstrated anti-fibrotic properties in clinical studies, reducing collagen buildup and supporting skin healing. A controlled clinical trial on 8% pirfenidone gel showed statistically significant scar regression in pediatric burn patients, suggesting a preventative effect on scar progression.
Evidence visible
A controlled clinical trial on 8% pirfenidone gel showed continuous monthly statistically significant scar regression over 6 months, with 27% of patients showing >55% decrease in Vancouver Scar Scale scores. The study concluded it was more effective than pressure therapy in treating hypertrophic scars.
Evidence visible
The clinical trial using 8% pirfenidone gel showed improvement in all scar features, which includes softening and flattening, as measured by the Vancouver Scar Scale. Pirfenidone works by inhibiting excessive collagen production.
Evidence visible
While the clinical study on pirfenidone gel showed overall scar regression and improvement in scar features, specific quantification of 'lightening' was not detailed in the summaries. However, improved texture and reduced redness (inflammation management) can contribute to a lighter appearance.
Evidence visible
The clinical trial demonstrated significant scar regression and improvement in overall scar features, which directly relates to improved skin texture. Reduced redness and inflammation also contribute to a more even skin tone.
Evidence visible
A safety evaluation study for Pirfesca (PIRFENIDONE GEL 8% w/w) assessed comedogenicity, skin irritability, allergenicity, and photoirritation, concluding it is non-irritant, hypoallergenic, non-comedogenic, and non-photoirritant.
Evidence visible
The gel format and presence of silicones (Polydimethylsiloxane, Cyclopentasiloxane, Phenyl Trimethicone, Dimethicone) support claims of non-greasy and fast-absorbing texture. This is a common characteristic of silicone-based gels.
Mentioned only
The safety evaluation study confirmed the product is non-irritant, hypoallergenic, non-comedogenic, and non-photoirritant, supporting its suitability for various skin types.
Evidence visible
Pirfenidone is a known broad-spectrum antifibrotic agent that modulates fibroblast activity and downregulates cytokines like TGF-β1, reducing collagen and fibrotic markers. This mechanism is well-documented in ingredient-level and finished-product studies.
Evidence visible
Pirfenidone has anti-inflammatory effects. The clinical study showed overall improvement in scar features, which would include reduction in redness and irritation associated with inflammation. The safety study also confirmed non-irritancy.
Evidence visible
This analysis evaluates brand claims against visible evidence and formula logic. It does not replace a full ingredient safety analysis or a clinical product test. Results vary by individual, and the consumer should always read the full ingredient list and follow usage guidance.
Are you the brand? If you have published test data or want to request a re-analysis, write to us at hello@thecleansheet.in.